Compare
Cullinan Therapeutics, Inc. vs Monte Rosa Therapeutics, Inc. vs REGENXBIO Inc. vs Vor Biopharma Inc.
| Latest fiscal year | Cullinan Therapeutics, Inc. CGEMRevenue covers only part of its income (partial revenue) | Monte Rosa Therapeutics, Inc. GLUE | REGENXBIO Inc. RGNX | Vor Biopharma Inc. VOR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $123.67M | $170.44M | n/a |
| Revenue growth (YoY) | n/a | +63.5% | +104.5% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -43.8% | -94.6% | n/a |
| Net margin | n/a | -31.2% | -113.8% | n/a |
| Net income | -$219.88M | -$38.63M | -$193.88M | -$695.98M |
| EPS (Diluted) | n/a | n/a | -$3.76 | -$70.50 |
| Operating cash flow | -$175.75M | -$22.80M | -$123.96M | -$142.71M |
| Free cash flow | -$175.80M | -$27.50M | -$126.38M | -$143.65M |
| Cash & equivalents | $88.33M | $129.88M | $34.47M | $396.49M |
| Total assets | $448.37M | $448.66M | $453.03M | $464.13M |
| Total liabilities | $39.64M | $215.60M | $350.30M | $628.44M |
| Shareholders' equity | $408.73M | $233.06M | $102.73M | -$164.31M |
| Return on year-end equity | -53.8% | -16.6% | -188.7% | n/a |
| Shares outstanding | 60.24M | 65.54M | 50.89M | 38.72M |
Revenue, most recent five fiscal years
| Fiscal year | Cullinan Therapeutics, Inc. | Monte Rosa Therapeutics, Inc. | REGENXBIO Inc. | Vor Biopharma Inc. |
|---|---|---|---|---|
| Latest | n/a | $123.67M Ended 2025-12-31 | $170.44M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $75.62M Ended 2024-12-31 | $83.33M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $90.24M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $112.72M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $470.35M Ended 2021-12-31 | n/a |